BioArctic AB (publ)

OM:BIOA B Rapporto sulle azioni

Cap. di mercato: SEK 16.1b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BioArctic Gestione

Gestione criteri di controllo 2/4

BioArctic's Il CEO è Gunilla Osswald, nominato in Jan2014, e ha un mandato di 10.58 anni. la retribuzione annua totale è SEK 22.38M, composta da 19.8% di stipendio e 80.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.11% delle azioni della società, per un valore di SEK 14.44M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.6 anni e 6.6 anni.

Informazioni chiave

Gunilla Osswald

Amministratore delegato

SEK 22.4m

Compenso totale

Percentuale dello stipendio del CEO19.8%
Mandato del CEO10.7yrs
Proprietà del CEO0.1%
Durata media del management5.7yrs
Durata media del Consiglio di amministrazione6.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 01
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Aug 15
Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

Apr 13
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 19
News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 03
News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Dec 23
Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Nov 12
With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Jul 21
BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Jul 15
Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Jul 07
New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

May 06
Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Mar 13
Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Nov 30
Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

Sep 16
We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow

Apr 04
We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow

We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth

Dec 05
We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth

BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate

Sep 15
BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate

BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business

Aug 23
BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Gunilla Osswald rispetto agli utili di BioArctic?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-SEK 88m

Mar 31 2024n/an/a

-SEK 122m

Dec 31 2023SEK 22mSEK 4m

SEK 229m

Sep 30 2023n/an/a

SEK 259m

Jun 30 2023n/an/a

SEK 270m

Mar 31 2023n/an/a

SEK 327m

Dec 31 2022SEK 9mSEK 5m

-SEK 11m

Sep 30 2022n/an/a

SEK 28m

Jun 30 2022n/an/a

-SEK 147m

Mar 31 2022n/an/a

-SEK 135m

Dec 31 2021SEK 5mSEK 3m

-SEK 120m

Sep 30 2021n/an/a

-SEK 114m

Jun 30 2021n/an/a

-SEK 97m

Mar 31 2021n/an/a

-SEK 101m

Dec 31 2020SEK 5mSEK 3m

-SEK 69m

Sep 30 2020n/an/a

-SEK 72m

Jun 30 2020n/an/a

-SEK 60m

Mar 31 2020n/an/a

SEK 78m

Dec 31 2019SEK 7mSEK 3m

SEK 88m

Sep 30 2019n/an/a

SEK 441m

Jun 30 2019n/an/a

SEK 475m

Mar 31 2019n/an/a

SEK 380m

Dec 31 2018SEK 5mSEK 3m

SEK 382m

Sep 30 2018n/an/a

SEK 58m

Jun 30 2018n/an/a

SEK 32m

Mar 31 2018n/an/a

SEK 29m

Dec 31 2017SEK 3mSEK 2m

SEK 15m

Compensazione vs Mercato: La retribuzione totale di Gunilla ($USD 2.17M ) è superiore alla media delle aziende di dimensioni simili nel mercato Swedish ($USD 778.42K ).

Compensazione vs guadagni: La retribuzione di Gunilla è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Gunilla Osswald (63 yo)

10.7yrs

Mandato

SEK 22,378,000

Compensazione

Dr. Gunilla Osswald, PhD has been the Chief Executive Officer and President of BioArctic AB (publ) since 2014. Dr. Osswald has been a Director of Egetis Therapeutics AB (publ) (formerly known as PledPharma...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Gunilla Osswald
President & CEO10.7yrsSEK 22.38m0.11%
SEK 17.2m
Pär Gellerfors
Co-Founder21.7yrsSEK 390.00kNessun dato
Lars Lannfelt
Co-Founder21.7yrsSEK 2.54m33.42%
SEK 5.4b
Anders Martin-Lof
Chief Financial Officer1.3yrsNessun datoNessun dato
Johanna Fälting
Chief Research Officer & Head of Researchno dataNessun dato0.051%
SEK 8.2m
Christer Möller
VP of Pre-Clinical Development & Chief Scientific Officer18.7yrsNessun dato0.063%
SEK 10.1m
Oskar Bosson
VP and Head of IR & Communication4.3yrsNessun dato0.016%
SEK 2.6m
Leif Gallo
General Counsel and Head of Legal & IPno dataNessun datoNessun dato
Harald Borgeke
Head of Public Affairs2.4yrsNessun datoNessun dato
Frida Lekander
Head of Marketing2.6yrsNessun datoNessun dato
Gunilla Andersson
Vice President of Human Resources5.7yrsNessun datoNessun dato
Mikael Moge
VP & Head of CMCno dataNessun dato0.011%
SEK 1.7m

5.7yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di BIOA B è esperto e expertise (durata media dell'incarico 5.6 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Pär Gellerfors
Co-Founder21.7yrsSEK 390.00kNessun dato
Lars Lannfelt
Co-Founder21.7yrsSEK 2.54m33.42%
SEK 5.4b
Eugen Steiner
Independent Chairman7yrsSEK 621.00k0.10%
SEK 16.2m
Hans Wigzell
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Konrad Beyreuther
Member of the Scientific Boardno dataNessun datoNessun dato
Marie Edström
Independent Director1.3yrsSEK 187.00kNessun dato
Mikael Smedeby
Independent Director6.3yrsSEK 316.00k0.032%
SEK 5.1m
Charlotta Ljungqvist
Independent Director3.3yrsSEK 318.00k0.0036%
SEK 575.6k
Martin Ingelsson
Member of Scientific Boardno dataNessun datoNessun dato
Staffan Pauli
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Ken Marek
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Kaj Blennow
Member of Scientific Advisory Boardno dataNessun datoNessun dato

6.7yrs

Durata media

70yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BIOA B sono considerati esperti (durata media dell'incarico 6.6 anni).